Ahead of its Investor Day, BCE (TSX: BCE) (NYSE: BCE) unveiled its three-year strategic plan focused on delivering sustainable growth through fibre, wireless, AI-powered enterprise solutions and ...
(NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA ® (tucatinib) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback